UniProtKB/Swiss-Prot P02533: Variant p.Ala94Thr

Keratin, type I cytoskeletal 14
Gene: KRT14
Feedback?

Variant information Variant position:

94 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Alanine (A) to Threonine (T) at position 94 (A94T, p.Ala94Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from small size and hydrophobic (A) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs3826550 [ dbSNP | Ensembl ]

Sequence information Variant position:

94 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

472 The length of the canonical sequence.
Location on the sequence:

SSSSSSFGSGFGGGYGGGLG A GLGGGFGGGFAGGDGLLVGS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SSSS------SSFG--------SGFGGGYGGGLGAGLGGGFGGGFAG--GDGLLVGS

Mouse                         SSSSFGGGLGSGFGGRF-----DGFGGGFGGGLGGGFGGGL

Rat                           SSSSFGGGFGGGIGGGIGGGLGGGIGGGFGGGIGGGFGGGI

Chicken                       CSSV-GGGLGGGFG--------ASYGAGYGAGFGGGFGAGF

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 472	Keratin, type I cytoskeletal 14
Region	1 – 114	Head

Literature citations
Cloning of human full-length CDSs in BD Creator(TM) system donor vector.
Kalnine N.; Chen X.; Rolfs A.; Halleck A.; Hines L.; Eisenstein S.; Koundinya M.; Raphael J.; Moreira D.; Kelley T.; LaBaer J.; Lin Y.; Phelan M.; Farmer A.;
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANTS TYR-63 AND THR-94; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANTS TYR-63 AND THR-94; Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with epidermolysis bullosa simplex: correlation between genotype and phenotype.
Soerensen C.B.; Ladekjaer-Mikkelsen A.-S.; Andresen B.S.; Brandrup F.; Veien N.K.; Buus S.K.; Anton-Lamprecht I.; Kruse T.A.; Jensen P.K.A.; Eiberg H.; Bolund L.; Gregersen N.;
J. Invest. Dermatol. 112:184-190(1999)
Cited for: VARIANT EBS1C ASN-116; VARIANT EBS1A SER-123; VARIANT EBS1B PRO-143; VARIANT THR-94; SEQUENCE REVISION TO 25 AND 43;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.